In Silico Interaction Studies of Various Antioxidant Molecules with MAO-B Protein – A Potent Secondary Drug Target in Parkinson’s Disease

S Ida Poornima; V Judia Harriet Sumathy

doi:10.17485/IJST/v15i19.2270

Article

In Silico Interaction Studies of Various Antioxidant Molecules with MAO-B Protein – A Potent Secondary Drug Target in Parkinson’s Disease

VIEWS 695
PDF 568

Indian Journal of Science and Technology

DOI: 10.17485/IJST/v15i19.2270

Year: 2022, Volume: 15, Issue: 19, Pages: 923-926

Original Article

In Silico Interaction Studies of Various Antioxidant Molecules with MAO-B Protein – A Potent Secondary Drug Target in Parkinson’s Disease

S Ida Poornima^1*, V Judia Harriet Sumathy²

¹Research scholar, PG & Research Department of Biotechnology, Women’s Christian College, Chennai
²Assistant Professor, Advanced Zoology and Biotechnology, Women’s Christian College, Chennai

*Corresponding Author
Email: [email protected]

Received Date:05 December 2021, Accepted Date:21 April 2022, Published Date:25 May 2022

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

Objective: Parkinson’s Disease (PD) remains to be the second prominent neurodegenerative disorder affecting the oldster populace. Administration of dopamine is the existing therapeutic choice to treat PD disorder. Contradictorily, administrated dopamine is readily oxidised by monoamine oxidase type B (MAOB) protein. Thus, MAOB is a potent secondary drug target for treating PD. The main objective of this present investigation is to compare, analyse and conclude the best adjuvant drug for the PD therapy. Methods: Molecules with high antioxidant properties were shortlisted for this study. This in-silico study was carried out by utilising several bioinformatics tools such as Patch Dock, Discovery studio software and CPHmodels-3.0. Findings: Alpha Tocopherol and Essential long chain fatty acids exhibited a good affinity binding scores than the existing adjuvant therapy drugs. The atomic contact energy of the docked complex of Alpha Tocopherol - MAOB is -373.83 Kcal/Mol and Docosahexaenoic Acid (DHA) - MAOB is -322.77 Kcal/Mol. Alpha Tocopherol and DHA was more significant than the Safinamide-MAOB complex with the atomic energy of - 302 Kcal/Mol. Novelty: The present study has comprehensively compared the in-silico interaction of various PD adjuvant drugs with the MAOB target and revealed the better MAOB inhibitor with their detailed interaction map and atomic contact energy.

Keywords: Parkinson’s Disease; MAOB; Essential fatty acids; Selegiline; Tocopherol; MAOB inhibitors

References

NLDR, Quiroga-Varela A, Fernanzo-Santiago R, Monje M, Trigo-Damas I, Blanco-Prieto M, et al. Advances in Parkinson’s Disease: 200years later. Frontiers in Neuroanatomy. 2020;12(113):1–14. doi: 10.3389/fnana.2018.00113
Rui Q, Ni H, Li D, Gao R, Chen G. The Role of LRRK2 in Neurodegeneration of Parkinson Disease. Current Neuropharmacology. 2018;16(9):1348–1357. Available from: https://dx.doi.org/10.2174/1570159x16666180222165418
Alecu I, Bennett SAL. Dysregulated Lipid Metabolism and Its Role in α-Synucleinopathy in Parkinson’s Disease. Frontiers in Neuroscience. 2019;13(328):1–22. doi: 10.3389/fnins.2019.00328
Levopoda. Levopoda, convectionally used Anti-parkinson’s drugs. Its pharmacodynamics and mode of action. 2021. Available from: https://go.drugbank.com/drugs/DB01235accesseddate
Jin CF, Wang ZZ, Chen KZ, Xu TF, Hao GF. Computational Fragment-Based Design Facilitates Discovery of Potent and Selective Monoamine Oxidase-B (MAO-B) Inhibitor. Journal of Medicinal Chemistry. 2020;63(23):15021–15036. Available from: https://dx.doi.org/10.1021/acs.jmedchem.0c01663
Elkamhawy A, Woo J, Gouda NA, Kim J, Nada H, Roh EJ, et al. Melatonin Analogues Potently Inhibit MAO-B and Protect PC12 Cells against Oxidative Stress. Antioxidants. 2021;10(10):1604. Available from: https://dx.doi.org/10.3390/antiox10101604
Tandarić T, Vianello R. Computational Insight into the Mechanism of the Irreversible Inhibition of Monoamine Oxidase Enzymes by the Antiparkinsonian Propargylamine Inhibitors Rasagiline and Selegiline. ACS Chemical Neuroscience. 2019;10(8):3532–3542. Available from: https://dx.doi.org/10.1021/acschemneuro.9b00147
Schirinzi T, Martella G, Imbriani P, Lazzaro GD, Franco D, Colona VL, et al. Dietary Vitamin E as a Protective Factor for Parkinson's Disease: Clinical and Experimental Evidence. Frontiers in Neurology. 2019;10(148). Available from: https://dx.doi.org/10.3389/fneur.2019.00148
Sun Q, Qu Y, Chen X, Xu MM. Relationship between high dietary fat intake and Parkinson’s disease risk: a meta-analysis. Neural Regeneration Research. 2019;14(12):2156. Available from: https://dx.doi.org/10.4103/1673-5374.262599
Angelova PR, Horrocks MH, Klenerman D, Gandhi S, Abramov AY, Shchepinov MS. Lipid peroxidation is essential for α-synuclein-induced cell death. Journal of Neurochemistry. 2015;133(4):582–589. Available from: https://dx.doi.org/10.1111/jnc.13024
Avallone R, Vitale G, Bertolotti M. Omega-3 Fatty Acids and Neurodegenerative Diseases: New Evidence in Clinical Trials. International Journal of Molecular Sciences. 2019;20(17):4256. Available from: https://dx.doi.org/10.3390/ijms20174256

Copyright

© 2022 Poornima & Sumathy. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Published By Indian Society for Education and Environment (iSee)